Novavax, Inc. (NASDAQ:NVAX - Get Free Report) has been given a consensus rating of "Hold" by the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $17.83.
Separately, HC Wainwright restated a "buy" rating and set a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th.
Check Out Our Latest Analysis on Novavax
Shares of NASDAQ NVAX opened at $8.19 on Wednesday. The firm has a fifty day simple moving average of $8.74 and a two-hundred day simple moving average of $10.26. The firm has a market capitalization of $1.31 billion, a PE ratio of -3.62, a price-to-earnings-growth ratio of 63.06 and a beta of 2.14. Novavax has a 12 month low of $3.81 and a 12 month high of $23.86.
Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.07. The business had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. The firm's revenue was down 54.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.26) earnings per share. On average, sell-side analysts predict that Novavax will post -1.31 earnings per share for the current year.
In other news, Director Rachel K. King sold 4,150 shares of Novavax stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the sale, the director now owns 14,770 shares in the company, valued at $133,225.40. This trade represents a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James F. Young sold 5,400 shares of the business's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares in the company, valued at $414,080. This represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,150 shares of company stock valued at $119,641 over the last 90 days. 1.00% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Spire Wealth Management purchased a new position in Novavax during the fourth quarter worth $29,000. New Age Alpha Advisors LLC purchased a new position in Novavax during the fourth quarter worth $35,000. KBC Group NV boosted its stake in Novavax by 97.0% during the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 3,917 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock worth $77,000 after buying an additional 1,598 shares during the period. Finally, TigerOak Management L.L.C. purchased a new position in Novavax during the fourth quarter worth $86,000. 53.04% of the stock is owned by hedge funds and other institutional investors.
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.